Skip to main content
TipRanks
Go Ultimate75% OFF

Perseus Proteomics, Inc. (4882) AI Stock Analysis

1 Followers
JP:4882

Perseus Proteomics, Inc.

(TSE/TYO:4882)

Select Model
Rating:42Neutral
Price Target:JPY 115.00â–²(0.00% Upside)
Action:reiterated
Date:09/09/26

The overall score is heavily pressured by the company's weak financial performance, marked by significant and ongoing net losses and negative cash flows, despite a debt-free balance sheet. The negative P/E ratio further underscores the lack of profitability. Short-term technical momentum provides a slight positive counterbalance, but the stock remains in a longer-term downtrend.

Positive Factors
Multi-year revenue growthRevenue has roughly doubled across the reported period, indicating that the company is expanding its commercial base and achieving sustained demand growth. Continued top-line progress can provide greater operating leverage if management converts that scale into narrower losses and stronger cash generation.
Negative Factors
Persistent operating lossesRecurring EBIT and net losses show that revenue growth and gross profitability are not yet sufficient to cover the company’s operating cost base. Until losses narrow materially, the business has limited internal earnings capacity, making durable profitability and shareholder returns difficult to establish.

Perseus Proteomics, Inc. (4882) vs. iShares MSCI Japan ETF (EWJ)

-80%-60%-40%-20%0%20%40%JP:4882-61.02%EWJ+16.38%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 2.01B
Dividend Yield
―
Average Volume (3M)
475.92K
Price to Earnings (P/E)
-2.4
Beta (1Y)
1.68
Revenue Growth
4.28%
EPS Growth
15.93%
Country
Japan
Employees
35
Sector
General
Sector Strength
55
Industry
Drug Manufacturers - General

Perseus Proteomics, Inc. Business Overview & Revenue Model

Company Description

Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alo...

How the Company Makes Money

null

Perseus Proteomics, Inc. Financial Statement Overview

Summary

Revenue is growing and the balance sheet is debt-free, but the company is deeply unprofitable with net losses exceeding revenue and negative cash flows. The overall financial health is poor, driven by the Income Statement (30) and Cash Flow (25) scores, only partially offset by a moderate Balance Sheet (55).

Income Statement

30Negative

Balance Sheet

55Neutral

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue147.22M135.51M120.38M100.40M94.20M71.93M
Gross Profit126.49M116.16M104.05M87.69M86.53M67.75M
EBITDA-744.74M-715.80M-899.49M-1.10B-779.36M-594.14M
Net Income-744.64M-718.11M-904.80M-1.10B-787.00M-599.02M
Balance Sheet
Total Assets1.67B1.62B1.82B1.69B2.57B3.30B
Cash, Cash Equivalents and Short-Term Investments1.59B1.52B1.67B1.54B2.44B3.21B
Total Debt000000
Total Liabilities442.44M405.77M386.43M295.46M170.10M148.38M
Stockholders Equity1.22B1.22B1.43B1.40B2.40B3.15B
Cash Flow
Free Cash Flow0-662.83M-794.64M-976.90M-734.82M-510.71M
Operating Cash Flow0-653.33M-719.49M-833.90M-564.27M-476.84M
Investing Cash Flow0-10.06M-75.16M-150.34M-212.99M-33.87M
Financing Cash Flow0497.33M923.38M63.94M-20.00K2.65B

Perseus Proteomics, Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price115.00

Price Trends

50DMA149.80Negative
100DMA149.75Negative
200DMA181.35Negative

Market Momentum

MACD-8.54Positive
RSI30.11Neutral
STOCH21.27Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4882, the sentiment is Negative. The current price of 115.00 is below the 20-day moving average (MA) of 133.05, below the 50-day MA of 149.80, and below the 200-day MA of 181.35, indicating a bearish trend. The MACD of -8.54 indicates Positive momentum. The RSI at 30.11 is Neutral, neither overbought nor oversold. The STOCH value of 21.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4882.

Perseus Proteomics, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4882 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:6090JP:609068NeutralJPY 3.31B10.61―3.22%7.98%61.76%
JP:7707JP:770768NeutralJPY 5.23B11.10―1.06%9.27%―
JP:3386JP:338667NeutralJPY 7.01B20.82―4.13%7.17%36.23%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:2342JP:234244NeutralJPY 3.07B-165.15――8.53%97.93%
JP:4882JP:488242NeutralJPY 2.12B-2.39――4.28%15.93%
JP:4978JP:497842NeutralJPY 11.33B-24.37――-8.23%-48.10%

* General Sector Average

Performance Comparison

-50%0%50%100%JP:4882JP:2342JP:3386JP:4978JP:6090JP:7707Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4882 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4882Perseus Proteomics, Inc.115.00-192.00-62.54%
JP:2342Trans Genic Inc.182.00-29.00-13.74%
JP:3386Cosmo Bio Co., Ltd.1210.00-93.10-7.14%
JP:4978ReproCELL Inc.106.00-54.00-33.75%
JP:6090Human Metabolome Technologies, Inc.559.00-99.72-15.14%
JP:7707Precision System Science Co.,Ltd189.00-11.00-5.50%

Perseus Proteomics, Inc. Corporate Events

FY2027/3 First-Half Business Results Material

Nov 17, 2026

Perseus Proteomics Inc. is identified in the supplied material, which does not state its industry, primary products or services, or market focus.The material is titled FY2027/3 First-Half Business Results and dated November 17, 2026; the supplied tex...

Perseus Proteomics Recognizes Non-operating Items and Impairment Loss

Nov 13, 2026

Perseus Proteomics Inc. announced that, for the six months ended September 30, 2026, it recognized non-operating income comprising subsidy income of 19,316 thousand yen, insurance income of 10,000 thousand yen, and interest income of 3,329 thousand y...

Perseus Proteomics Reports Six-Month Results Without FY2027 Forecast

Nov 13, 2026

Perseus Proteomics Inc., listed on the Tokyo Stock Exchange, reported net sales of ¥52 million for the six months ended September 30, 2026, down 13.7% year over year, while operating, ordinary and net losses were ¥411 million, ¥394 million and ¥399 m...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 09, 2026